questionText: To ask the Secretary of State for Health and Social Care, what information his Department holds on the potential thyroid cancer risk from Mounjaro; when his Department received this information; whether he has made an assessment of the potential impact of the provision of Mounjaro through the NHS on the risk of thyroid cancer; whether the Medicines and Healthcare products Regulatory Agency has requested information from the US Food and Drug Administration on its interim report on this matter of March 2024; and for what reason the risk-labelling for Mounjaro is different in the UK to that used in the US.
answerText: The Medicines and Healthcare products Regulatory Agency’s (MHRA) role is to continually monitor the safety of medicines during their use. We have robust, safety monitoring and surveillance systems in place for all healthcare products. New medicines such a...
heading: Tirzepatide